Evidence map›Paper›PMID 34500748›Full record

ArticleMolecules (Basel, Switzerland)2021

Amorphous Form of Carvedilol Phosphate-The Case of Divergent Properties.

Szymon Sip, Natalia Rosiak, Andrzej Miklaszewski, Patrycja Talarska, Ewa Dudziec, Judyta Cielecka-Piontek

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Szymon SipDepartment of Pharmacognosy, Poznan University of Medical Sciences, 4 Swiecickiego Street, 60-781 Poznan, Poland.ORCID 0000-0002-6618-9956
Natalia RosiakDepartment of Pharmacognosy, Poznan University of Medical Sciences, 4 Swiecickiego Street, 60-781 Poznan, Poland.ORCID 0000-0003-4722-6413
Andrzej MiklaszewskiInstitute of Materials Science and Engineering, Poznan University of Technology, Jana Pawła II 24, 61-138 Poznan, Poland.ORCID 0000-0001-6792-4281
Patrycja TalarskaDepartment of Immunobiology, Poznan University of Medical Sciences, ul. Rokietnicka 8, 60-806 Poznan, Poland.ORCID 0000-0003-1305-0990
Ewa DudziecDepartment of Rheumatology and Rehabilitation, Poznan University of Medical Sciences, ul. 28 Czerwca 1956 r. 135/147, 61-545 Poznan, Poland.
Judyta Cielecka-PiontekDepartment of Pharmacognosy, Poznan University of Medical Sciences, 4 Swiecickiego Street, 60-781 Poznan, Poland.ORCID 0000-0003-0891-5419
Poznan University of Medical Sciences · PLPoznań University of Technology · PL

Funding

National Science Center Poland 2013/09/D/NZ7/02525
6 · The paper itself

Abstract

The amorphous form of carvedilol phosphate (CVD) was obtained as a result of grinding. The identity of the obtained amorphous form was confirmed by powder X-ray diffraction (PXRD), different scanning calorimetry (DSC), and FT-IR spectroscopy. The process was optimized in order to obtain the appropriate efficiency and time. The crystalline form of CVD was used as the reference standard. Solid dispersions of crystalline and amorphous CVD forms with hydrophilic polymers (hydroxypropyl-β-cyclodextrin, Pluronic

Indexed as

amorphouscarvedilol phosphatedissolution ratepermeabilitysolid dispersion

Identifiers

PMID34500748
PMCPMC8434513
OpenAlexW3197114011

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.